Poly Medicure Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹441Cr
- +16.7% YoY
- +4% QoQ
- Net profit
- ₹92Cr
- +35.3% YoY
- +8.2% QoQ
- Margin
- 27%
- +1 pp YoY
- 0 pp QoQ
Guidance rank: #4 of 13 in Healthcare Equipment & Supplies
See the sector's top 10 — free with your mobile number.
The short version
The Company targets overall revenue growth of around 20% in the current year. Poly Medicure targets a revenue growth of around 20% overall for FY '26.
From Poly Medicure Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The Company targets overall revenue growth of around 20% in the current year.
- Domestic business growth is expected to be robust, at approximately 30%-32%.
- Renal business is projected to grow significantly, with about 50%-60% growth anticipated for FY '26.
- Infusion (vascular access) domestic business is expected to grow at 18%-20% this year.
- Export revenue growth is forecast to be between 12%-15%, with Europe remaining a prime market.
- Renal market share in India is expected to rise from current 10%-12% to 15%-17% over the next 2-3 years.
- Installed base of dialysis machines aims to increase to 500-600 units sold annually, supporting growth in renal segment.
2 more points from Poly Medicure Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Poly Medicure Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Poly Medicure Limited is on a heavy CAPEX cycle with a planned investment of around Rs. 500 crores over the next 2 years.
- CAPEX is focused on building 3 new manufacturing facilities in Haryana, Uttarakhand, and Rajasthan.
- Two sites are already under construction, with the third expected to start soon, aiming for commercialization by end of Calendar Year 2026.
- Investments will primarily expand Renal capacity and explore new opportunities in the CDMO space leveraging new tariff structures.
- About Rs. 900 crores of recently raised QIP funds remain unutilized and will be partly used for CAPEX, working capital, and general corporate purposes.
2 more points from Poly Medicure Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Poly Medicure Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Poly Medicure Ltd said on order book & pipeline — free account, 30 seconds.
Poly Medicure Ltd — Quarterly revenue & net profit
Poly Medicure Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 441 | 378 | +16.7% | 424 | +4% |
| Operating profit (EBITDA) | 119 | 96 | +24% | 114 | +4.4% |
| Operating margin | 27% | 26% | +1 pp | 27% | 0 pp |
| Profit before tax | 123 | 92 | +33.7% | 113 | +8.8% |
| Net profit (PAT) | 92 | 68 | +35.3% | 85 | +8.2% |
| EPS (₹) | 9.06 | 7.12 | +27.2% | 8.41 | +7.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹581 Cr, net profit ₹95 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Poly Medicure's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Vaidya Sane (Q4 FY25)
120 crores. Key concall takeaways from Vaidya Sane Ayurved Laboratories Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- OSEL Devices (Q4 FY25)
Current order-in-hand for OSEL Devices Limited is approximately INR 40-45 crores. Key concall takeaways from OSEL Devices Ltd's Q4 FY25 earnings call — and how…
- Prevest Denpro (Q4 FY25)
The management emphasizes growth in both domestic and export markets, indicating healthy order inflows aligned with a 13% sales increase in FY25. Key concall…
- Aprameya Enginee (Q4 FY25)
Current order book: Approximately INR 60 crores. Key concall takeaways from Aprameya Engineering Ltd's Q4 FY25 earnings call — and how it ranks against sector…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Molbio DiagnostiGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Poly Medicure Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Poly Medicure Ltd Q4 FY25 results?
The Company targets overall revenue growth of around 20% in the current year. Poly Medicure targets a revenue growth of around 20% overall for FY '26.
What is Poly Medicure Ltd share price analysis?
Poly Medicure Ltd currently shows a neutral. The stock trades at a P/E of 52.9 with a market cap of ₹17,317 Cr. Investors should review the full earnings analysis for detailed insights.
Is Poly Medicure Ltd planning capital expenditure?
Poly Medicure Limited is on a heavy CAPEX cycle with a planned investment of around Rs. 500 crores over the next 2 years.
Keep Poly Medicure Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
